CM-95 solution magnetically treated as prevention and therapy of radiodermitis in patients with cancer
Keywords:
cancer, radiodermitis, radiotherapy, CM-95 solution, magnetic treatment.Abstract
A descriptive and longitudinal cases and controls investigation, of 75 patients with cancer in different locations, admitted to "Conrado Benítez García" Teaching Provincial Cancer Hospital in Santiago de Cuba, in one year, was carried out to evaluate the effectiveness of the CM-95 solution magnetically treated in the prevention and treatment of radiodermitis, applied before and after the radiotherapy by means of topical and oral dose of 15 mL in the 24 members of the study group, as long as, in the control group (27 patients) the same solution was applied without magnetizing; the rest conformed a group (also control group) that didn't receive any of the solutions. In many of the cases the radiodermitis didn't appear and it was not necessary to interrupt the radiotherapy or its suspension time diminished in 7 days, while in the controls the clinical entity was more presented and the clinical course time to renew the radiations was of 15 and 23 days. Most of the patients of the study group improved the adverse effects of radiotherapy, as gastritis, rectitis, diarrheas, lack of appetite, acute distress, and they maintained the hematological parameters in the normal limits.Downloads
Download data is not yet available.
References
1. Salazar GJ, Candiani O. Dermatitis por radiación. Generalidades y su asociación con cetuximab. Med Cutan Iber Lat Am. 2010; 38(3): 127-33.
2. Feight D, Baney T, Bruce S, McQuestion M. Evidence-Based Interventions for Radiation Dermatitis. Clin J Oncol Nurs. 2011; 15(5):481-92.
3. McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011; 27: 1–17.
4. Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, et al. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol. 2010; 17(4): 94–112.
5. Jensen JM, Gau T, Schultze J, Lemmnitz G, Fölster-Holst R, May T, et al. Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial. Strahlenther Onkol. 2011; 187: 378–84.
6. Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011 [citado 14 Dic 2015]; (4). Disponible en: http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD000978.pub5/full
7. González Calzadilla ME, Céspedes Quevedo MC, González Calzadilla I, Infante Carbonell MC, Vinent Céspedes AM. Reacciones adversas al tratamiento radiante en el adulto mayor con cáncer. MEDISAN. 2015 [citado 14 Dic 2015]; 19(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192015000100004
8. Di Franco R, Sammarco R, Grazia CM, Flora De Natale F, Falivene S, Di Leche A, et al. Preventing the acute skin side effects in patients treated with radiotherapy for breast cancer: the use of corneometry in order to evaluate the protective effect of moisturizing creams. Radiation Oncol. 2013; 8(57): 1748-71.
9. Pardo Masferrer J, Murcia Mejía M, Vidal Fernández M, Alvarado Astudillo A, Hernández Armenteros ML, Macías Hernández V, et al. Prophylaxis with a cream containing urea reduces the incidence and severity of radio-induced dermatitis. Clin Transl Oncol. 2010; 12(1):43-8.
10. Ryan L. Ionizing radiation: the good, the bad, and the ugly. Journal of Investigative Dermatology. 2012; 132: 985–93.
11. Martínez CE, Cobas G, Lebeque Y, Fontaine R, Pérez I, Almenares J, et al. Evaluación de la sustancia CM-95 tratada magnéticamente como inmunopotenciador con antígenos de Pseudomonas aeruginosa. Biotecnol Aplic. 2003; 20: 22-5.
12. Martínez CE, Pérez I, Morris H, Fontainer R. Efectos de la Solución de sales CM-95 tratada magnéticamente sobre células mononucleares. Biotecnol Aplic. 2004; 21: 224-8.
13. Martínez CE, Díaz AJ, Alfonso A, Pardo TA, Betancourt JE, Fuente E, et al. Toxicidad por dosis repetidas de la solución CM-95 tratada magnéticamente en ratas Sprague Dawley. VacciMonitor. 2008; 17(2): 8-25.
14. Martínez CE, Toledano M, Rodríguez G, Andina L, Lassalle I, Sierra G. Solución adyuvante CM-95 tratada magnéticamente en comparación con el adyuvante de Freud para la obtención del suero de Coombs en conejo. VacciMonitor. 2009; 18(3): 5-12.
15. Martínez C, Tamayo V, Favier P, Castillo JR, Hernández R, Sierra G. Efecto inmunomodulador de la solución CM-95 tratada magnéticamente en ratones Balb/c inoculados con 5-fluorouracilo. VacciMonitor. 2011; 20: 13-21.
16. Gozzo T de O, Panobianco MS, Clapis MJ, De Almeida A. Dermatological toxicity in women with breast cancer undergoing chemotherapy treatment. Rev Lat Am Enfermagem. 2010; 18(4): 681-7.
17. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012; 67: 1265-72.
18. Abbas AK, Lichtman HA, Pillai S. Cellular and Molecular Immunology. 7 ed. Madrid: Elsevier; 2012.
2. Feight D, Baney T, Bruce S, McQuestion M. Evidence-Based Interventions for Radiation Dermatitis. Clin J Oncol Nurs. 2011; 15(5):481-92.
3. McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011; 27: 1–17.
4. Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, et al. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol. 2010; 17(4): 94–112.
5. Jensen JM, Gau T, Schultze J, Lemmnitz G, Fölster-Holst R, May T, et al. Treatment of acute radiodermatitis with an oil-in-water emulsion following radiation therapy for breast cancer: a controlled, randomized trial. Strahlenther Onkol. 2011; 187: 378–84.
6. Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011 [citado 14 Dic 2015]; (4). Disponible en: http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD000978.pub5/full
7. González Calzadilla ME, Céspedes Quevedo MC, González Calzadilla I, Infante Carbonell MC, Vinent Céspedes AM. Reacciones adversas al tratamiento radiante en el adulto mayor con cáncer. MEDISAN. 2015 [citado 14 Dic 2015]; 19(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192015000100004
8. Di Franco R, Sammarco R, Grazia CM, Flora De Natale F, Falivene S, Di Leche A, et al. Preventing the acute skin side effects in patients treated with radiotherapy for breast cancer: the use of corneometry in order to evaluate the protective effect of moisturizing creams. Radiation Oncol. 2013; 8(57): 1748-71.
9. Pardo Masferrer J, Murcia Mejía M, Vidal Fernández M, Alvarado Astudillo A, Hernández Armenteros ML, Macías Hernández V, et al. Prophylaxis with a cream containing urea reduces the incidence and severity of radio-induced dermatitis. Clin Transl Oncol. 2010; 12(1):43-8.
10. Ryan L. Ionizing radiation: the good, the bad, and the ugly. Journal of Investigative Dermatology. 2012; 132: 985–93.
11. Martínez CE, Cobas G, Lebeque Y, Fontaine R, Pérez I, Almenares J, et al. Evaluación de la sustancia CM-95 tratada magnéticamente como inmunopotenciador con antígenos de Pseudomonas aeruginosa. Biotecnol Aplic. 2003; 20: 22-5.
12. Martínez CE, Pérez I, Morris H, Fontainer R. Efectos de la Solución de sales CM-95 tratada magnéticamente sobre células mononucleares. Biotecnol Aplic. 2004; 21: 224-8.
13. Martínez CE, Díaz AJ, Alfonso A, Pardo TA, Betancourt JE, Fuente E, et al. Toxicidad por dosis repetidas de la solución CM-95 tratada magnéticamente en ratas Sprague Dawley. VacciMonitor. 2008; 17(2): 8-25.
14. Martínez CE, Toledano M, Rodríguez G, Andina L, Lassalle I, Sierra G. Solución adyuvante CM-95 tratada magnéticamente en comparación con el adyuvante de Freud para la obtención del suero de Coombs en conejo. VacciMonitor. 2009; 18(3): 5-12.
15. Martínez C, Tamayo V, Favier P, Castillo JR, Hernández R, Sierra G. Efecto inmunomodulador de la solución CM-95 tratada magnéticamente en ratones Balb/c inoculados con 5-fluorouracilo. VacciMonitor. 2011; 20: 13-21.
16. Gozzo T de O, Panobianco MS, Clapis MJ, De Almeida A. Dermatological toxicity in women with breast cancer undergoing chemotherapy treatment. Rev Lat Am Enfermagem. 2010; 18(4): 681-7.
17. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012; 67: 1265-72.
18. Abbas AK, Lichtman HA, Pillai S. Cellular and Molecular Immunology. 7 ed. Madrid: Elsevier; 2012.
Published
2016-11-07
How to Cite
1.
González Fernández S, Román Montoya A de la C, Martínez Manrique C, Batuti Bonne M, Fernández Fernández I. CM-95 solution magnetically treated as prevention and therapy of radiodermitis in patients with cancer. MEDISAN [Internet]. 2016 Nov. 7 [cited 2025 Jun. 4];20(11). Available from: https://medisan.sld.cu/index.php/san/article/view/670
Issue
Section
Original Articles
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
